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Abstract
Older patients are at increased risk of toxicities from aggressive oncologic therapy
and of nononcologic death. A meta-analysis of non-nasopharyngeal head and
neck cancers showed no statistical benefit in adding chemotherapy to radiotherapy (RT) in older patients; another meta-analysis of RT versus chemoradiotherapy (CRT) in NPC found advantages to CRT, but vastly under-represented
patients ≥70 years old. This is the largest study to date evaluating outcomes of
CRT versus RT alone in this population. The National Cancer Data Base (NCDB)
was queried for primary nasopharyngeal cancer cases (2004–2013) in patients
≥70 years old receiving RT alone or CRT. Patients with unknown RT/chemotherapy and T1N0 or M1 disease were excluded. Logistic regression analysis
ascertained factors associated with CRT delivery. Kaplan–Meier analysis evaluated
overall survival (OS) between both cohorts. Cox proportional hazards modeling
determined variables associated with OS. In total, 930 patients were analyzed
(n = 713 (77%) CRT, n = 217 (23%) RT). Groups were relatively balanced;
CRT was less frequently delivered in patients with advancing age, lower nodal
burden, and females (P < 0.05 for all). Median OS in the CRT and RT groups
were 35.3 versus 20.0 months, respectively (P = 0.002). On multivariate analysis,
independent predictors of OS included age, comorbidities, income and insurance
status, tumor grade, and stage (P < 0.05 for all). Notably, receipt of chemotherapy independently predicted for improved OS (P = 0.036). CRT, compared
to RT alone, was independently associated with improved survival in NPC patients ≥70 years old. CRT appears to be a promising approach in this population,
but treatment-related toxicity risks should continue to be weighed against potential oncologic benefits.

Introduction
Numerous clinical trials have demonstrated survival
improvements with the addition of chemotherapy to definitive radiation therapy (RT) for head and neck cancers,
as highlighted by the MACH-NC meta-analysis [1]. One
important result of this study, however, was a decreasing
benefit to chemotherapy with increasing age, which was
independent of other covariates analyzed. Moreover, nearly
40% of deaths in patients ≥71 years of age therein were
1604

not cancer-
related. Although the meta-
analysis did not
evaluate toxicities, numerous studies have illustrated
decreased tolerance of oncologic therapies by older patients
[2–4].
A factor limiting applicability of the MACH-NC report
was its specific exclusion of nasopharyngeal cancer (NPC).
This neoplasm, rare in the United States but endemic in
south China and north Africa, is most commonly treated
with chemoradiotherapy (CRT) [5]. This paradigm is
supported by the MAC-
NPC meta-
analysis, which
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demonstrated an overall survival (OS) benefit of 6% at
5 years with the addition of chemotherapy to RT [6].
However, that analysis notably underrepresented older
patients, likely related to the median age of NPC patients
being approximately 55 years (in the United States) [7].
Just 13% of the total MAC-
NPC cohort was ≥60 years
of age; although the proportion ≥70 years old was not
reported, it is likely less than half of that figure.
As a result, optimal management for older (defined as
≥70 years old herein) NPC patients with respect to the
additional chemotherapy is currently not well defined.
Although challenging to assess with single-or multi-
institutional analyses owing to the relative rarity of older
NPC patients, the National Cancer Data Base (NCDB)
provides a unique resource with which to address this
novel but clinically important issue. In this investigation,
the largest such study to date, we evaluated national practice patterns and outcomes in older NPC patients treated
with CRT versus RT alone.

and to isolate the effect of adding chemotherapy to RT
[5]. Other exclusion criteria were incomplete staging information, palliative care treatment, and unknown information on RT and/or chemotherapy. In accordance with the
variables in NCDB files, information collected on each
patient broadly included demographic, clinical, and treatment data.
All statistical tests were performed with SPSS software
(IBM Corporation, Armonk, NY); tests were two-
sided,
with a threshold of P < 0.05 for statistical significance.
Univariable and multivariable logistic regression were used
to determine characteristics associated with receipt of CRT.
All initially examined variables were considered for inclusion into models for stepwise selection. Survival analysis
(performed using Kaplan–Meier methodology) evaluated
OS, defined as the interval between the date of diagnosis
and the date of death or censored at last contact. Univariate
and multivariate Cox proportional hazards modeling was
utilized to evaluate predictors of OS.

Materials & Methods

Results

The NCDB is a joint project of the Commission on Cancer
(CoC) of the American College of Surgeons and the
American Cancer Society, which consists of de-identified
information regarding tumor characteristics, patient demographics, and patient survival for approximately 70% of
the United States population [8–15]. All pertinent cases
are reported regularly from CoC-
accredited centers and
compiled into a unified dataset, which is then validated.
The NCDB contains information not included in the
Surveillance, Epidemiology, and End Results database,
including details regarding use of systemic therapy. The
data used in the study were derived from a de-identified
NCDB file (2004–2013). The American College of Surgeons
and the CoC have not verified and are neither responsible
for the analytic or statistical methodology employed nor
the conclusions drawn from these data by the investigators. As all patient information in the NCDB database is
de-
identified, this study was exempt from institutional
review board evaluation.
Inclusion criteria for this study were patients ≥70 years
of age with newly-diagnosed nasopharyngeal cancer treated
with RT for curative intent. The 70-
year-
old threshold
was utilized because it is among the most commonly
used cutoff to denote “older” patients in head/neck cancer
as well as many other areas of oncology [16]; it is also
close to the threshold utilized in the MACH-
NC study
[1]. T1N0 and M1 cases were excluded because CRT is
not the consensus-
based recognized treatment for these
subsets; patients receiving any form of pharyngectomy
were similarly removed because it is nonstandard for NPC

A complete flow diagram of patient selection is provided
in Figure 1. In total, 930 patients met study analysis
criteria. Table 1 displays notable clinical characteristics
of the analyzed patients, most (74%) of whom were
70–79 years of age. A total of 713 (77%) patients underwent CRT, whereas 217 (23%) received RT alone. After
univariable analysis was performed to assess factors associated with receipt of CRT, multivariable assessment
revealed that factors independently associated with
decreased likelihood of CRT delivery were advancing age
(P = 0.001), female gender (P = 0.014), and node-negative
disease (P = 0.002). There was also a trend toward
increasing CRT receipt in more recent years (2009–2013,
P = 0.063).
Median
follow-
up
was
23
months
(range,
0–129 months). Kaplan–Meier estimates comparing OS
in patients that received RT alone versus CRT are illustrated in Figure 2; median OS in the respective cohorts
were 20.0 (95% confidence interval (CI), 12.8–27.3) months
and 35.3 (95% CI, 29.3–41.2) months (P = 0.002).
In the overall cohort, there were several predictors of
OS on univariate analysis (Table 2). After multivariate
adjustment for potential confounding factors (Table 2),
factors independently associated with poorer OS included
advancing age, comorbidity index, lower income, Medicare
insurance (relative to private), poor/undifferentiated/anaplastic disease, and stage IV (M0) disease (P < 0.05 for
all). Of note, receipt of CRT relative to RT alone independently predicted for improved OS (hazard ratio, 0.721,
95% CI, 0.532–0.979, P = 0.036).

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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Naonal Cancer Data Base
nasopharyngeal cases from 2004 to 2013
(n = 12,389)

Age < 70
(n = 10,231)

No or unknown radiotherapy
(n = 446)

Pharyngectomy performed
(n = 33)

Incomplete staging, T1N0, or M1
(n = 642)

Unknown chemotherapy status
(n = 54)

Palliave care
(n = 53)

Study populaon
(n = 930)

Chemoradiotherapy
(n = 713)

Radiotherapy alone
(n = 217)

Figure 1. Patient selection diagram.

Discussion
To the best of our knowledge, this is the largest report
assessing practice patterns and outcomes of RT with or
without chemotherapy for elderly NPC patients. Our study
of a large national database of this relatively uncommon
clinical circumstance notably demonstrates that the addition of chemotherapy to RT is independently associated
with greater survival in older patients, indicating that the
benefit of chemotherapy in NPC may extend potentially
to all ages.
A main message from our analysis is that causation is
not implied; it could very well be that patients receiving

1606

RT alone were not healthy enough to receive additional
chemotherapy, and hence they would naturally do worse
and be at greater risk of dying from noncancer causes
as mentioned above. Although the lack of endpoints such
as cancer-
specific survival and local/regional control in
the NCDB hampers firm conclusions, there are several
reasons to believe this bias may be relatively minimal.
First, cohorts were relatively balanced, including no differences in Charlson-
Deyo comorbidity index (although
this does not equate to performance status, it did independently predict for OS on Cox multivariate analysis
herein). In fact, because groups were overall quite balanced,
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Table 1. Characteristics of the overall cohort and factors associated with receiving chemoradiotherapy.
Parameter, N (%) or median
(range)

CRT
(N = 713)

RT Alone
(N = 217)

Age (years)
Median (range)
75 (70–90)
79 (70–90)
Gender
Male
467 (66%)
110 (51%)
Female
246 (34%)
107 (49%)
Race
White
522 (73%)
166 (76%)
Black
65 (9%)
18 (8%)
Other
106 (15%)
26 (12%)
Unknown
20 (3%)
7 (3%)
Charlson deyo score1
0
541 (76%)
158 (73%)
1
129 (18%)
43 (20%)
≥2
43 (6%)
16 (7%)
Insurance type
Uninsured
3 (0%)
0 (0%)
Private
88 (12%)
29 (13%)
Medicaid/Other Government
31 (4%)
10 (5%)
(non-Medicare)
Medicare
580 (81%)
174 (80%)
Unknown
9 (1%)
4 (2%)
Income (US dollars/year)
<$30,000
127 (18%)
44 (20%)
$30,000–$34,999
157 (22%)
52 (24%)
$35,000–$45,999
195 (27%)
57 (26%)
≥$46,000
226 (32%)
57 (26%)
Unknown
6 (1%)
7 (3%)
Location
Metro
596 (84%)
174 (80%)
Urban
85 (12%)
31 (14%)
Rural
9 (1%)
2 (1%)
Unknown
23 (3%)
10 (5%)
Percentage of adults in zip code without high school diploma
≥21%
137 (19%)
38 (18%)
13–20.9%
186 (26%)
61 (28%)
7–12.9%
233 (33%)
68 (31%)
<7%
149 (21%)
44 (20%)
Unknown
8 (1%)
6 (3%)
Facility type
Community
385 (54%)
134 (62%)
Academic
328 (46%)
83 (38%)
Facility location
Northeast
174 (24%)
39 (18%)
South
223 (31%)
76 (35%)
Midwest
175 (25%)
60 (28%)
West
141 (20%)
42 (19%)
Distance to treating facility (mi)
Median (range)
8 (0–2456)
7 (0–1736)
Year of Diagnosis
2004–2008
330 (46%)
117 (54%)
2009–2013
383 (54%)
100 (46%)
Tumor grade
Well or moderate
138 (19%)
38 (18%)
Poorly, undifferentiated,
384 (54%)
99 (46%)
anaplastic
Unknown
191 (27%)
80 (37%)

Univariable

Multivariable (stepwise)

OR (95% CI)

P-value

OR (95% CI)

P-value

0.542 (0.398–0.737)

0.001

0.860 (0.832–0.888)

0.001

1.161 (1.125–1.198)
REF

0.001

1.534 (1.089–2.161)
REF

0.014

0.723 (0.514–1.017)
REF

0.063

REF
0.871 (0.502–1.510)
0.771 (0.485–1.226)
–

0.622
0.272
–

REF
1.141 (0.774–1.682)
1.274 (0.699–2.323)

0.504
0.429

–
1.098 (0.699–1.727)
1.075 (0.517–2.237)

–
0.684
0.846

REF
–

–

REF
0.956 (0.601–1.521)
0.844 (0.537–1.326)
0.728 (0.464–1.141)
–

0.849
0.462
0.166
–

REF
1.249 (0.801–1.949)
0.761 (0.163–3.556)
–

0.327
0.761
–

REF
1.182 (0.745–1.875)
1.052 (0.671–1.649)
1.065 (0.651–1.742)
–

0.477
0.825
0.803
–

REF
1.375 (1.008–1.877)

0.044

REF
0.752 (0.461–1.227)
1.144 (0.743–1.762)
1.151 (0.732–1.810)

0.254
0.541
0.542

1.000 (0.999–1.001)

0.510

0.736 (0.543–0.999)
REF

0.049

REF
1.068 (0.701–1.628)

0.759

–

–
(Continued)
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(Continued).

Parameter, N (%) or median
(range)
T classification
X
1
2
3
4
N classification
0
1
2
3
Unknown
Group stage
II
III
IV
Unknown

CRT
(N = 713)

RT Alone
(N = 217)

Univariable

Multivariable (stepwise)

OR (95% CI)

P-value

0.604
0.149
0.571
0.800

21 (3%)
147 (21%)
203 (28%)
137 (19%)
205 (29%)

6 (3%)
33 (15%)
72 (33%)
41 (19%)
65 (30%)

REF
1.577 (0.282–8.808)
0.708 (0.443–1.132)
1.119 (0.759–1.648)
0.944 (0.604–1.475)

193 (27%)
237 (33%)
196 (27%)
52 (7%)
35 (5%)

103 (47%)
53 (24%)
43 (20%)
7 (3%)
11 (5%)

0.396 (0.238–0.554)
0.630 (0.127–1.133)
0.661 (0.161–1.161)
REF
–

0.001
0.238
0.263

94 (13%)
233 (33%)
284 (40%)
102 (14%)

34 (16%)
64 (29%)
75 (35%)
44 (20%)

1.370 (0.858–2.186)
1.040 (0.714–1.515)
REF
–

0.187
0.837

–

–

OR (95% CI)

P-value

0.252 (0.107–0.603)
0.570 (0.236–1.379)
0.614 (0.251–1.503)
REF
–

0.002
0.213
0.263

–

–

–

Statistically significant P-values (P < 0.05) are in bold. Only values included in the final multivariable model are shown. CRT, chemoradiotherapy; RT,
radiotherapy; OR, odds ratio; CI, confidence interval.
1The Charlson-Deyo index is a weighted score of comorbidities as defined by several medical codes.

Figure 2. Kaplan–Meier overall survival curve comparing those receiving
radiotherapy alone (green) versus chemoradiotherapy (blue).

there was relatively little indication for propensity matching, which would have prohibitively eliminated sample
size from an already limited patient population.
Furthermore, there were only three variables significantly
different between groups on multivariable logistic regression analysis (age, gender, and nodal status); of those
three variables, the CRT cohort was younger but had a
1608

higher proportion of node-
positive disease and males.
Younger age has been shown to associate with more
advanced disease [17]; node-
positivity and male gender
also correlate with poorer prognosis [18–20]. In this manner, consistent with other work, it is plausible that chemotherapy potentially may have been given to a “higher-risk”
population, and that there may be “true” benefits to adding
chemotherapy [21, 22].
Despite the large dataset offered by the NCDB, one
of its major limitations is a lack of toxicity assessment.
To this extent, smaller retrospective reports of older NPC
patients (which have employed varying definitions of
“older/elderly”) suggest that despite the increase in acute
toxicities when adding chemotherapy to RT, these may
not be worse in severity from those experienced by younger
patients [23, 24]. This is consistent with multiple studies
in other head/neck neoplasms showing similar toxicities
and/or outcomes in elderly patients as compared to their
younger counterparts [2, 25–27]. Thus, we encourage
judicious and individualized judgment when evaluating
administration of CRT in elderly NPC patients; there
will likely never be a “definitive answer” regarding aggressive therapies (vs. lack thereof) in elderly patients, owing
to retrospective patient selection biases and varying definitions of “older/elderly” patients from study to study.
We, therefore, propose that the term “older/elderly”
should not be singularly defined by age, because these
patients are intrinsically heterogeneous [28]. Rather, utilization of many available measures to measure functionality
(e.g., the Comprehensive Geriatric Assessment) and

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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Table 2. Univariate and multivariate Cox proportional hazards model for overall survival.
Univariate

Multivariate

Parameter

HR

95% CI

P-value

HR

95% CI

P-value

Treatment group (CRT vs. RT alone)
Age (continuous)
Gender (male vs. female)
Race (black vs. white)
Race (others vs. white)
Charlson–Deyo score (0 vs. 2)
Charlson–Deyo score (1 vs. 2)
Insurance (uninsured vs. Medicare)
Insurance (private vs. Medicare)
Insurance (Medicaid/other government vs. Medicare)
Income (<$30,000 vs. $30,000–$34,999)
Income (<$30,000 vs. $35,000–$45,999)
Income (<$30,000 vs. ≥$46,000)
Location (urban vs. metro)
Location (rural vs. metro)
Percentage of adults in zip code without high school
diploma (13–20.9% vs. ≥21%)
Percentage of adults in zip code without high school
diploma (7–12.9% vs. ≥21%)
Percentage of adults in zip code without high school
diploma (<7% vs. ≥21%)
Facility type (academic vs. community)
Facility location (South vs. Northeast)
Facility location (Midwest vs. Northeast)
Facility location (West vs. Northeast)
Distance to treatment facility (continuous)
Year of diagnosis (2004–2008 vs. 2009–2013)
Grade (poor/undifferentiated/anaplastic vs. well/
moderate)
T classification (x vs. 1)
T classification (x vs. 2)
T classification (x vs. 3)
T classification (x vs. 4)
N classification (0 vs. 1)
N classification (0 vs. 2)
N classification (0 vs. 3)
Group stage (II vs. IV)
Group stage (III vs. IV)

0.735
1.053
0.864
0.845
0.262
0.517
0.609
2.252
0.613
0.629
1.584
1.403
1.323
1.384
1.777
1.125

0.606–0.892
1.036–1.069
0.725–1.030
0.625–1.144
0.468–0.823
0.377–0.710
0.426–0.872
0.560–9.052
0.459–0.852
0.387–1.022
1.233–2.035
1.097–1.794
1.047–1.671
1.080–1.773
0.841–3.757
0.851–1.486

0.002
0.001
0.103
0.276
0.001
0.001
0.007
0.253
0.001
0.061
0.001
0.019
0.039
0.010
0.132
0.408

0.721
1.063

0.532–0.979
1.037–1.090

0.036
0.001

0.517
0.609
2.752
0.553
0.700
1.584
1.403
1.323

0.377–0.710
0.426–0.872
0.374–20.234
0.359–0.852
0.377–1.298
1.233–2.035
1.097–1.703
1.047–1.671

0.001
0.001
0.320
0.007
0.257
0.001
0.007
0.019

1.267

0.986–1.629

0.065

1.049

0.820–1.341

0.704

1.146
1.143
1.289
1.301
1.000
0.981
1.691

0.962–1.366
0.867–1.507
1.001–1.658
1.000–1.693
0.999–1.000
0.815–1.182
1.356–2.110

0.126
0.344
0.049
0.050
0.515
0.843
0.001

1.510

1.163–1.962

0.002

0.326
0.404
0.494
0.532
0.548
0.695
0.612
0.497
0.619

0.104–1.022
0.311–0.525
0.397–0.614
0.411–0.698
0.379–0.792
0.481–1.003
0.426–0.879
0.358–0.691
0.505–0.759

0.055
0.001
0.001
0.001
0.001
0.052
0.008
0.001
0.001

0.530
0.550

0.359–0.783
0.423–0.716

0.001
0.001

Statistically significant P values (P < 0.05) are in bold. Only values included in the final multivariate model are shown.
HR, hazard ratio; CI, confidence interval; CRT, chemoradiotherapy; RT, radiotherapy.

performance status (PS) is a more reliable way to divide
“older/elderly” patients into the “functionally older/elderly”
or “functionally young” [29]. For instance, Liu and colleagues did not find a benefit to adding chemotherapy
to RT in NPC patients with high comorbidity indices
[23]. This study was underpowered to confirm those
findings. Nevertheless, these and other parameters are
critically important in adequately selecting “elderly” patients
that are “fit” to receive aggressive oncologic therapies.
Lastly, although one method to reduce toxicities of CRT
is delivering chemotherapy and RT sequentially, we were
unable to separately ascertain the benefit of concurrent

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

versus sequential CRT. In our dataset, a large majority
(77%) of CRT patients received chemotherapy and RT
within 2 weeks of each other (two weeks being a previously utilized cutoff point for concurrent therapy in prior
such publications [30]). Of the remaining 23% of the
CRT cohort, timing of therapies was unknown in 7%,
indicating that just 16% certainly received sequential CRT.
This was much too small of a sample size to analyze
separately in this study. Hence, induction chemotherapy
followed by RT remains an attractive option in well-selected
“older” NPC patients at higher risk of toxicities.
Additionally, although the use of induction chemotherapy
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followed by CRT could emerge as a new standard of care
[31], the phase III trial deliberately excluded patients
≥60 years of age owing to toxicity risks. However, retrospective data of patients ≥60 years treated with CRT
with or without induction chemotherapy showed no outcome differences, with higher toxicities in those receiving
induction therapy [32].
Although the NCDB provides a unique platform for
studying this important clinical question, this investigation
still has limitations. First, NCDB studies are inherently
retrospective, with selection biases and lack of several
endpoints as mentioned above. Second, NCDB does not
keep track of precise chemotherapy details, including specific chemotherapeutic agents, reasons for withholding
chemotherapy in RT alone patients (ie. related to tolerability vs. disease- related factors), or the number of cycles
of chemotherapy received. Third, the NCDB does not
allow for an assessment of subsequent lines of treatment
(e.g., re-irradiation, further systemic and/or targeted therapy), which could influence OS. Furthermore, the NCDB
also does not provide details such as performance/functional status, Epstein–Barr virus status, or radiotherapy
field design/volumes/techniques. Fourth, a major limitation
of this study was too few patients for a statistically reliable
subset analysis of whether benefit to CRT is limited to
those with advanced versus limited nodal disease. The
NCDB is also unique to the United States and thus may
not be representative to other areas of the world where
NPC is endemic.

Conclusions
This is the largest study to date evaluating the utility of
CRT, as compared to RT alone, for older (≥70 years old)
patients with NPC. Administration of CRT was independently associated with improved survival, but causation
is not implied, and careful patient selection is necessary
to balance treatment-related toxicity risks with potential
oncologic benefits.
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